Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCP NASDAQ:INCR NASDAQ:MCRB NASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$0.94+0.7%$1.05$0.86▼$2.67$12.91M1.411.14 million shs20,057 shsINCRInterCure$0.94+3.6%$0.97$0.68▼$1.77$51.40M1.3951,376 shs12,052 shsMCRBSeres Therapeutics$5.23-0.4%$6.90$5.00▼$29.98$50.63M0.0972,785 shs28,770 shsTCRTAlaunos Therapeutics$1.95-6.7%$2.29$1.67▼$4.59$47.62M-1.0217,751 shs9,991 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma+0.01%-1.08%-6.52%-36.73%-42.23%INCRInterCure-0.31%-8.36%-2.32%+12.00%-41.47%MCRBSeres Therapeutics+2.74%-1.69%-20.57%-37.80%-62.09%TCRTAlaunos Therapeutics+2.20%0.00%-2.79%-23.44%-32.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$0.94+0.7%$1.05$0.86▼$2.67$12.91M1.411.14 million shs20,057 shsINCRInterCure$0.94+3.6%$0.97$0.68▼$1.77$51.40M1.3951,376 shs12,052 shsMCRBSeres Therapeutics$5.23-0.4%$6.90$5.00▼$29.98$50.63M0.0972,785 shs28,770 shsTCRTAlaunos Therapeutics$1.95-6.7%$2.29$1.67▼$4.59$47.62M-1.0217,751 shs9,991 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma+0.01%-1.08%-6.52%-36.73%-42.23%INCRInterCure-0.31%-8.36%-2.32%+12.00%-41.47%MCRBSeres Therapeutics+2.74%-1.69%-20.57%-37.80%-62.09%TCRTAlaunos Therapeutics+2.20%0.00%-2.79%-23.44%-32.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 1.00SellN/AN/AINCRInterCure 1.00SellN/AN/AMCRBSeres Therapeutics 2.25Hold$17.00225.05% UpsideTCRTAlaunos Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest COCP, TCRT, MCRB, and INCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/23/2026MCRBSeres Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/23/2026MCRBSeres Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/23/2026MCRBSeres Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/8/2026COCPCocrystal Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026COCPCocrystal Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal Pharma$225K57.37N/AN/A$0.46 per share2.04INCRInterCure$270.20M0.19N/AN/A$2.11 per share0.45MCRBSeres Therapeutics$790K64.08$1.11 per share4.70$4.89 per share1.07TCRTAlaunos Therapeutics$3K15,874.30N/AN/A$0.93 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$8.83M-$0.73N/AN/AN/AN/A-150.61%-97.86%8/13/2026 (Estimated)INCRInterCure-$10.37M$0.0331.33N/AN/AN/AN/AN/AN/AMCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)TCRTAlaunos Therapeutics-$4.18M-$2.13N/AN/AN/AN/A-165.94%-123.50%8/18/2026 (Estimated)Latest COCP, TCRT, MCRB, and INCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026N/ACOCPCocrystal Pharma-$0.17N/AN/AN/A$0.23 millionN/A8/5/2026Q2 2026MCRBSeres Therapeutics-$2.1850N/AN/AN/A$0.18 millionN/A5/15/2026Q1 2026COCPCocrystal Pharma-$0.15-$0.17-$0.02-$0.17$0.23 million$0.23 million5/15/2026Q1 2026TCRTAlaunos TherapeuticsN/A-$0.59N/A-$0.59N/AN/A5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A2.662.66INCRInterCure0.201.480.97MCRBSeres TherapeuticsN/A1.651.65TCRTAlaunos TherapeuticsN/A1.631.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%INCRInterCure8.34%MCRBSeres Therapeutics59.34%TCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma39.40%INCRInterCure0.24%MCRBSeres Therapeutics5.20%TCRTAlaunos Therapeutics16.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1013.79 million8.36 millionNot OptionableINCRInterCure35054.68 millionN/AOptionableMCRBSeres Therapeutics3309.68 million9.18 millionOptionableTCRTAlaunos Therapeutics4024.42 million20.48 millionNo DataCOCP, TCRT, MCRB, and INCR HeadlinesRecent News About These CompaniesAlaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse StudyJune 29, 2026 | markets.businessinsider.comAlaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | finanznachrichten.deAlaunos reports positive preclinical obesity drug results across weight, liver, insulin markersMay 26, 2026 | msn.comAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | globenewswire.comAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity ModelsMay 18, 2026 | globenewswire.comWeight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares DropMarch 2, 2026 | benzinga.comAlaunos Reports Positive Preclinical Data for Obesity CandidateMarch 2, 2026 | tipranks.comAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersMarch 2, 2026 | globenewswire.comAlaunos Therapeutics Reaches Settlement With MD Anderson CancerDecember 23, 2025 | tipranks.comAlaunos Therapeutics files to sell 327,740 shares of common for holdersOctober 22, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market ImplicationsAugust 12, 2025 | msn.comAlaunos Therapeutics Appoints Holger Weis as New CEOJuly 25, 2025 | theglobeandmail.comAlaunos Therapeutics Taps Board Member Weis as Next CEOJuly 2, 2025 | marketwatch.comAlaunos Therapeutics, Inc. (TCRT) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comAlaunos Therapeutics Raises $850,000 in Private OfferingJune 26, 2025 | tipranks.comAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering - MorningstarJune 24, 2025 | morningstar.comMAlaunos Therapeutics Announces $2.0 Million Registered Direct OfferingJune 23, 2025 | globenewswire.comAlaunos Therapeutics Amends Warrant Agreement with Mast HillJune 10, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOCP, TCRT, MCRB, and INCR Company DescriptionsCocrystal Pharma NASDAQ:COCP$0.94 +0.01 (+0.66%) Closing price 03:56 PM EasternExtended Trading$0.93 -0.01 (-0.56%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.InterCure NASDAQ:INCR$0.94 +0.03 (+3.62%) Closing price 03:53 PM EasternExtended Trading$0.96 +0.03 (+2.66%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Seres Therapeutics NASDAQ:MCRB$5.23 -0.02 (-0.38%) Closing price 04:00 PM EasternExtended Trading$5.28 +0.05 (+1.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Alaunos Therapeutics NASDAQ:TCRT$1.95 -0.14 (-6.70%) Closing price 03:59 PM EasternExtended Trading$1.98 +0.03 (+1.54%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
